Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Current Assets (2023 - 2026)

Alto Neuroscience has reported Current Assets over the past 4 years, most recently at $269.1 million for Q1 2026.

  • Quarterly results put Current Assets at $269.1 million for Q1 2026, up 64.58% from a year ago — trailing twelve months through Mar 2026 was $269.1 million (up 64.58% YoY), and the annual figure for FY2025 was $177.7 million, up 4.95%.
  • Current Assets reached $269.1 million in Q1 2026 per ANRO's latest filing, up from $177.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $269.1 million in Q1 2026 and bottomed at $85.4 million in Q4 2023.
  • Median Current Assets over the past 4 years was $173.5 million (2024), compared with a mean of $174.2 million.
  • The largest annual shift saw Current Assets surged 98.31% in 2024 before it fell 24.02% in 2025.
  • Over 4 years, Current Assets stood at $85.4 million in 2023, then soared by 98.31% to $169.3 million in 2024, then rose by 4.95% to $177.7 million in 2025, then surged by 51.43% to $269.1 million in 2026.
  • Business Quant data shows Current Assets for ANRO at $269.1 million in Q1 2026, $177.7 million in Q4 2025, and $139.4 million in Q3 2025.